Abstract
Objectives: To determine the frequency of disease reclassification and to identify clinicopathological variables associated with it in patients with favourable-risk prostate cancer undergoing active surveillance (AS). Patients and Methods: We assessed 191 men, selected by what may be the most stringent criteria used in AS studies yet conducted, who were enrolled in a prospective cohort AS trial. Clinicopathological characteristics were analysed in a multivariate Cox proportional hazards regression model. Key features were an extended biopsy with a single core positive for Gleason score (GS) 3 + 3 (<3 mm) or 3 + 4 (<2 mm) and a prostate-specific antigen (PSA) level <4 ng/mL (adjusted for prostate volume). Biopsies were repeated every 1–2 years and clinical evaluations every 6 months. Disease was reclassified when PSA level increased by 30% from baseline, or when biopsy tumour length increased beyond the enrolment criteria, more than one positive core was detected or any grade increased to a dominant 4 pattern or any 5 pattern. Results: Disease was reclassified in 32 patients (16.8%) including upgrading to GS 4 + 3 in five patients (2.6%). The median (interquartile range) follow-up time among survivors was 3 (1.9–4.6) years. Overall, 13 of the 32 (40.6%) had incremental increases in GS. Tumour length (hazard ratio 2.95, 95% confidence interval [CI] 1.34–6.46; P = 0.007) and older age (hazard ratio 1.05, 95% CI 1.00–1.09; P = 0.05) were identified as significant and marginally significant predictors of disease reclassification, respectively. Disease remained stable in 83.2% of patients. Conclusion: The need persists for improvements in risk stratification and predictive indicators of cancer progression.
Original language | English (US) |
---|---|
Pages (from-to) | 68-76 |
Number of pages | 9 |
Journal | BJU international |
Volume | 118 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1 2016 |
Keywords
- active surveillance
- biopsy
- prostate
- prostate cancer
- tumour
- watchful waiting
ASJC Scopus subject areas
- Urology
MD Anderson CCSG core facilities
- Biostatistics Resource Group